prikaz prve stranice dokumenta Resistance to KRAS inhibition in advanced non-small cell lung cancer
  Preuzmi
PDF 1.61 MB
Znanstveni rad - Pregledni rad
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Frontiers in Oncology, 14 (2024); 1357898. https://doi.org/10.3389/fonc.2024.1357898
Sreter, Katherina Bernadette; Catarata, Maria Joana; von Laffert, Maximilian; Frille, Armin

Citirajte ovaj rad

Sreter, K. B., Catarata, M. J., von Laffert, M. i Frille, A. (2024). Resistance to KRAS inhibition in advanced non-small cell lung cancer. Frontiers in Oncology, 14.. doi: 10.3389/fonc.2024.1357898

Sreter, Katherina Bernadette, et al. "Resistance to KRAS inhibition in advanced non-small cell lung cancer." Frontiers in Oncology, vol. 14, 2024. https://doi.org/10.3389/fonc.2024.1357898

Sreter, Katherina Bernadette, Maria Joana Catarata, Maximilian von Laffert i Armin Frille. "Resistance to KRAS inhibition in advanced non-small cell lung cancer." Frontiers in Oncology 14 (2024). https://doi.org/10.3389/fonc.2024.1357898

Sreter, K. B., et al. (2024) 'Resistance to KRAS inhibition in advanced non-small cell lung cancer', Frontiers in Oncology, 14. doi: 10.3389/fonc.2024.1357898

Sreter KB, Catarata MJ, von Laffert M, Frille A. Resistance to KRAS inhibition in advanced non-small cell lung cancer. Frontiers in Oncology [Internet]. 2024. [pristupljeno 08.12.2024.];14. doi: 10.3389/fonc.2024.1357898

K. B. Sreter, M. J. Catarata, M. von Laffert i A. Frille, "Resistance to KRAS inhibition in advanced non-small cell lung cancer", Frontiers in Oncology, vol. 14, 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:220:139949. [Citirano: 08.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:220:139949
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Resistance to KRAS inhibition in advanced non-small cell lung cancer
AutorKatherina Bernadette Sreter
AutorMaria Joana Catarata
AutorMaximilian von Laffert
AutorArmin Frille
Autorova ustanova(Klinički bolnički centar Sestre milosrdnice)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Sažetak (engleski)
Lung cancer remains the leading cause of cancer death globally. More than 50% of new cases are diagnosed in an advanced or metastatic stage, thus contributing to the poor survival of such patients. Mutations in the KRAS (Kirsten rat sarcoma virus) gene occur in nearly a third of lung adenocarcinoma and have for decades been deemed an ‘undruggable’ target. Yet, in recent years, a growing number of small molecules, such as the GTPase inhibitors, has been investigated in clinical trials of lung cancer patients harboring KRAS mutations, yielding promising results with improved outcomes. Currently, there are only two approved targeted therapies (adagrasib and sotorasib) for advanced or metastatic KRAS - mutated NSCLC from the second-line setting onwards. In this narrative review, we will focus on KRAS, its molecular basis, the role of its co-mutations, clinical evidence for its inhibition, putative mutation to resistance, and future strategies to overcome resistance to KRAS inhibition.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFrontiers in Oncology
Brojčani podacivol. 14, 1357898
e-ISSN2234-943X
DOIhttps://doi.org/10.3389/fonc.2024.1357898
URN:NBNurn:nbn:hr:220:139949
Datum objave publikacije2024
URL dokumentahttps://www.frontiersin.org/articles/10.3389/fonc.2024.1357898/full
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2024-09-25 12:38:03